Last 25 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.32 | — | — | — | — | — | — | — | 164.35 | — | 2.30 | 5.21 | — | 3.87 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 49.10 | 74.33 | 86.51 | 150.85 | 81.85 | 37.25 | 35.62 | 4.52 | 4.98 | 8.29 | 1.34 | 2.08 | 3.01 | 3.14 | 6.91 | 4.65 | — | — | — | — | — |
| — | +99.5% | +142.9% | +3240.8% | +1545.0% | +349.1% | +2566.2% | +116.6% | +65.4% | +164.1% | -80.7% | -55.1% | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.68 | 1.36 | 1.33 | 1.95 | 1.39 | 0.71 | 0.73 | 0.89 | 1.74 | 1.54 | 1.18 | 1.83 | 2.08 | 2.23 | 2.43 | 2.04 | 1.99 | 2.11 | 1.49 | 1.06 | 1.19 |
| — | +92.2% | +81.9% | +119.1% | -20.0% | -54.1% | -37.8% | -51.4% | -16.4% | -31.0% | -51.5% | -10.5% | +4.2% | +5.3% | +63.1% | +93.3% | +67.5% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 3.26 | — | — | — | — | 0.58 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | 1.77 | 5.57 | 22.34 | 9.54 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | 1.67 | 4.85 | 25.70 | 10.11 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.9% | 100.0% | 100.0% | 8.0% | 31.8% | -2276.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 49.3% | -44.7% | 8.5% | — | — | — | — | — |
| — | +104.4% | 0.0% | -92.0% | -68.2% | -2376.8% | 0.0% | 0.0% | 0.0% | +103.0% | +323.5% | +1070.5% | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -613.7% | -4606.5% | -5007.0% | -4834.6% | -3249.3% | -2915.2% | -2402.5% | -106.0% | -15.7% | -110.7% | 56.4% | 35.7% | 11.7% | 32.0% | -89.7% | -22.9% | — | — | — | — | — |
| — | -58.0% | -108.4% | -4461.3% | -20611.8% | -2534.1% | -4358.5% | -396.8% | -233.8% | -445.4% | +162.9% | +256.1% | — | — | — | — | — | — | — | — | — | |
| Net Margin | -565.5% | -4391.4% | -4762.0% | -4539.1% | -3014.9% | -2734.4% | -2210.4% | -84.4% | 3.0% | -71.7% | 58.1% | 39.7% | -22.8% | 81.1% | -142.7% | -26.4% | — | — | — | — | — |
| — | -60.6% | -115.4% | -5278.7% | -99793.6% | -3713.7% | -3903.5% | -312.3% | +113.3% | -188.4% | +140.7% | +250.4% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.1% | -18.4% | -17.0% | -13.8% | -12.1% | -12.3% | -10.8% | -4.1% | 0.3% | -3.3% | 15.7% | 9.2% | -3.9% | 15.6% | -11.9% | -3.0% | -11.1% | -10.3% | -8.7% | -7.5% | -16.3% |
| — | -50.2% | -56.8% | -235.6% | -4655.8% | -272.2% | -168.7% | -144.7% | +106.8% | -121.1% | +232.5% | +404.2% | +64.7% | +252.2% | -36.7% | +59.9% | +32.3% | — | — | +63.9% | — | |
| ROA | -31.8% | -14.0% | -13.5% | -11.1% | -9.9% | -10.2% | -9.2% | -3.4% | 0.2% | -2.5% | 10.1% | 4.8% | -2.0% | 7.2% | -5.3% | -1.8% | -9.4% | -8.8% | -7.6% | -7.0% | -8.4% |
| — | -37.1% | -46.3% | -225.2% | -4835.5% | -314.9% | -191.5% | -171.4% | +110.5% | -134.1% | +288.3% | +361.4% | +78.6% | +182.2% | +29.3% | +73.7% | -11.1% | +15.7% | -9.7% | — | +57.7% | |
| ROIC | -35.8% | -19.8% | -15.8% | -12.4% | -11.2% | -10.7% | -9.1% | -4.1% | -1.1% | -4.5% | 13.9% | 6.2% | 1.5% | 4.5% | -11.2% | -4.1% | -9.6% | -9.7% | -8.4% | -14.3% | — |
| — | -85.5% | -72.7% | -201.4% | -906.3% | -134.7% | -165.8% | -166.4% | -176.5% | -200.3% | +224.2% | +251.4% | +115.2% | +146.9% | -32.8% | +71.3% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.24 | 0.21 | 0.18 | 0.17 | 0.15 | 0.14 | 0.14 | 0.14 | 0.15 | 0.15 | 0.25 | 0.28 | 0.28 | 0.35 | 0.07 | 0.12 | 0.12 | 0.12 | 0.11 | — |
| — | +55.1% | +44.2% | +34.5% | +20.5% | +6.0% | -3.8% | -44.6% | -50.9% | -48.2% | -57.5% | +249.0% | +130.7% | +133.7% | +202.1% | -38.5% | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 1.19 | 3.01 | 12.10 | 4.65 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 12.53 | 7.85 | 10.89 | 13.90 | 12.53 | 14.08 | 18.64 | 21.88 | 11.15 | 6.59 | 5.70 | 2.38 | 2.33 | 2.32 | 3.10 | 2.94 | 9.55 | 10.89 | 14.05 | 17.68 | 44.46 |
| — | -44.3% | -41.6% | -36.4% | +12.4% | +113.7% | +226.7% | +818.7% | +378.6% | +184.7% | +84.1% | -19.0% | -75.6% | -78.7% | -77.9% | -83.4% | -78.5% | -36.9% | -53.7% | — | +273.8% | |
| Quick Ratio | 12.53 | 7.85 | 10.89 | 13.90 | 12.53 | 14.08 | 18.64 | 21.88 | 11.15 | 6.59 | 5.70 | 2.38 | 2.33 | 2.32 | 3.10 | 2.94 | 9.55 | 10.89 | 14.05 | 17.68 | 44.46 |
| — | -44.3% | -41.6% | -36.4% | +12.4% | +113.7% | +226.7% | +818.7% | +378.6% | +184.7% | +84.1% | -19.0% | -75.6% | -78.7% | -77.9% | -83.4% | -78.5% | -36.9% | -53.7% | — | +273.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TRDA stock.
Entrada Therapeutics, Inc.'s current P/E is -1.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Entrada Therapeutics, Inc.'s current operating margin is -613.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Entrada Therapeutics, Inc.'s business trajectory between earnings reports.